Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Wildervanck syndrome is characterized by the triad of cervical vertebral fusion (Klippel-Feil anomaly), bilateral abducens palsy with retracted eyes (Duane syndrome) and congenital perceptive deafness.
Features include: Preauricular skin tag, Hearing loss (hearing impairment), Fused cervical vertebrae, and Pseudopapilledema and 4 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Skin | 1 | Preauricular skin tag |
Ears |
Biomarker and diagnostic research for Wildervanck syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Wildervanck syndrome.
112 publications have been identified in PubMed for Wildervanck syndrome. Research spans Basic Science / Preclinical (40%), Review / Meta-Analysis (31%), and Clinical Trial Publication (13%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 45 | 40% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 7:49 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Wildervanck syndrome
1
Hearing loss (hearing impairment) |
Bones and joints | 1 | Fused cervical vertebrae |
Head and neck | 1 | Facial asymmetry |
35 |
31% |
Clinical study results | 15 | 13% |
Patient case studies | 7 | 6% |
Disease patterns and progression | 6 | 5% |
Testing and diagnosis research | 3 | 3% |
New treatment approaches | 1 | 1% |
Li H (2026). [PMID: 41365194](https://pubmed.ncbi.nlm.nih.gov/41365194/). *Phytomedicine*. [Basic Science / Preclinical]
Corral Nieto Y (2026). [PMID: 41803642](https://pubmed.ncbi.nlm.nih.gov/41803642/). *Autophagy*. [Basic Science / Preclinical]
Zhang H (2026). [PMID: 41442992](https://pubmed.ncbi.nlm.nih.gov/41442992/). *Phytomedicine*. [Basic Science / Preclinical]
Raposeiras-Roubín S (2026). [PMID: 41200807](https://pubmed.ncbi.nlm.nih.gov/41200807/). *Circulation*. [Clinical Trial Publication]
Hohneck A (2026). [PMID: 41366604](https://pubmed.ncbi.nlm.nih.gov/41366604/). *Herz*. [Review / Meta-Analysis]
Tanaka A (2026). [PMID: 41423223](https://pubmed.ncbi.nlm.nih.gov/41423223/). *J Atheroscler Thromb*. [Review / Meta-Analysis]
Ni D (2026). [PMID: 41274422](https://pubmed.ncbi.nlm.nih.gov/41274422/). *Prog Biophys Mol Biol*. [Review / Meta-Analysis]
Ibrahim SY (2026). [PMID: 32809672](https://pubmed.ncbi.nlm.nih.gov/32809672/). *Unknown Journal*. [Basic Science / Preclinical]
Jin BH (2025). [PMID: 40937579](https://pubmed.ncbi.nlm.nih.gov/40937579/). *Int J Mol Med*. [Basic Science / Preclinical]
Spadafora L (2025). [PMID: 40555879](https://pubmed.ncbi.nlm.nih.gov/40555879/). *Am J Cardiovasc Drugs*. [Diagnostic / Biomarker]